MOH single-door for health industry under the purview of MaHTAS is established to streamline the internal process for health tech development, assessment, adoption and implementation in Ministry of Health. This initiative aims to empower health industry players and local innovators to drive technology advancements.
What we do? (based on each unit)
The facilitation services provided include:
01
Early scientific advice for health technology development and scientific evidence generation
02
Facilitation of testing in healthcare facilities
03
Health technology introduction
Activities / output type
*subject to activity
Product Introduction
The primary role of this platform is to introduce the new health technology to stakeholders, ensuring a clear understanding of its features, benefits, and value proposition. This involves the industry to deliver a concise and engaging overview of the product, and demonstrating how it addresses customer needs or overcame current challenges. Additionally, this platform will provide opportunity for relevant stakeholders to provide feedback on the health technology.
Product Development
Early dialogue offers a platform for open communication between key stakeholders to gather insights, define needs, and explore opportunities. This involves engaging users and technical teams with industry / researchers in a structured discussions to identify needs, prioritize features, evidence generation and align expectations. The goal is to ensure that diverse perspectives are captured early in the development process, enabling more informed decision-making and setting a solid foundation for product design, scope, and direction.
Pharmaceutical Information Proforma
This form is for pharmaceutical use only and should be completed with full details on the product, its use, and supporting evidence. The information will support evaluation of new pharmaceuticals for patient care and healthcare impact in Malaysia.
Health Technology Information Proforma
This form is for submissions on medical devices, regenerative technologies, biologics, interventions/procedures, diagnostics, and traditional or complementary medicines. It should be completed with relevant product details and evidence to support assessment of its safety, effectiveness, and impact on healthcare in Malaysia.